Study on new drug JMT103 vs zoledronic acid for bone metastases
Treatments studied
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests a new drug, JMT103, against a standard treatment (zoledronic acid) to see if it better prevents bone problems in people whose cancer has spread to the bones. If you have breast, prostate, lung, or another solid tumor with bone metastases, this study may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have breast, prostate, lung, or another solid tumor that has spread to at least one bone.
- If you have prostate cancer, it must be castration-resistant and still progressing despite treatment.
- Your organs are working well enough for the study.
- Your doctor expects you to live at least 6 more months.
- You have not had jaw problems (like osteonecrosis or recent dental surgery) and do not need major dental work soon.
- You have not taken drugs like bisphosphonates or similar within the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called JMT108 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to see if the drug is safe and how it affects the body.
This real-world study looks at how the medicine zoledronic acid affects bone-related problems in people with breast cancer that has spread to the bone. It may help reduce events like fractures or other bone complications by protecting bone health.
This Phase 3 study tests narlumosbart (JMT103) to see if it works and is safe for people with giant cell tumor of bone that cannot be fully removed with surgery. If you qualify, you may be compared against another treatment and monitored closely for side effects and tumor response.
This trial studies how tyrosine kinase inhibitor (TKI) medicines work against non-small cell lung cancer that has spread to the bone. It’s for people with specific “actionable” gene changes, to see how well these treatments reduce or change bone metastases.
This trial is testing a new medicine called JMT106 for people with advanced solid tumors (cancers that have spread or can't be removed). It's for patients whose cancer has not responded to or can't use other treatments, and who have not had a therapy targeting a specific protein (GPC3) before.
This trial tests a new drug called JMT108 for people with advanced solid tumors that haven't responded to standard treatments. It aims to find out if the drug is safe and how well it works against cancer.
Hear when a new Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.